Reports
Sale
Global Doxorubicin Market Size, Price, Growth, Trends, Report: By Application: Ovarian Cancer, Multiple Myeloma, Kaposi Sarcoma, Leukaemia, Bone Sarcoma, Breast Cancer, Endometrial Cancer, Gastric Cancer, Liver Cancer, Kidney Cancer, Other Cancers; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
Global Doxorubicin Market Outlook
The global doxorubicin market size attained a value of USD 1,295.95 million in 2023 driven highly by the rising incidences of cancer across the globe. The market is anticipated to grow at a CAGR of 6.4% during the forecast period of 2024-2032 to attain a value of USD 2,264.98 million by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Breast Cancer Segment to Hold a Significant Market Share of the Market Over the Forecast Period
Doxorubicin finds its largest regional market in North America. The region is expected to retain its dominance over the global market in the coming years owing to the increase in cancer incidence and associated mortality rate. The United States registered the highest cancer rate and considerable deaths in 2020. Meanwhile, the regional market in the Asia Pacific is estimated to grow with healthy CAGR over the period owing to the highest mortality rate in China. In terms of application, the most prevalent cancers include breast cancer, prostate cancer, lung cancer, colon and rectum cancer, and skin melanoma. Hence, the segment of breast cancer is projected to account for the maximum use of the drug in the coming years. According to WHO, the number of breast cancer cases found in the year 2020 was around 2.26 million, which is about 11.7% of all the new cases registered that year.
Doxorubicin: Market Segmentation
Doxorubicin (C27H29NO11) is a medication for chemotherapy used in the treatment of various cancer diseases, including breast cancer, bladder cancer, lymphoma, and others. It is administered as an intravenous drug along with other chemotherapy agents and is sold under different brand names including Adriamycin, and Caelyx, among others.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The applications for doxorubicin include:
- Ovarian Cancer
- Multiple Myeloma
- Kaposi Sarcoma
- Leukaemia
- Bone Sarcoma
- Breast Cancer
- Endometrial Cancer
- Gastric Cancer
- Liver Cancer
- Kidney Cancer
- Other Cancer
The EMR report looks into the regional markets of doxorubicin like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rising Cancer Cases and Related Deaths to Bolster the Demand for Doxorubicin
The primary driver for the market growth of doxorubicin is the rising incidences of cancer across the globe. This increase can be attributed to the presence of carcinogens in day-to-day use products in the current lifestyle of people. According to the latest statistics provided by the Union for International Cancer Control (UICC), the number of cancer cases has risen to 19.3 million and 10 million cancer related deaths in 2020. This rise is expected to continue in the forthcoming years, providing lucrative opportunities for demand growth of doxorubicin. Additionally, supportive actions from the government for technological progress in clinical diagnostics and therapeutics such as intravenous free therapy and digital microfluidics for biochemical analysis is expected to boost the market growth of the drug over the forecast period. However, it is noteworthy that certain side effects, such as hand-foot syndrome, typhlitis, heart failure, among others, can potentially impede the growing demand.
Key Industry Players in the Global Doxorubicin Market
The report presents a detailed analysis of the following key players in the global doxorubicin market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Pfizer Inc.
- Sun Pharmaceutical Industries Limited
- Cipla, Inc.
- Cadila Pharmaceuticals Ltd.
- Others
The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Application |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Doxorubicin Market Overview
3.1 Global Doxorubicin Market Historical Value (2017-2023)
3.2 Global Doxorubicin Market Forecast Value (2024-2032)
4 Global Doxorubicin Market Landscape
4.1 Global Doxorubicin Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Doxorubicin Product Landscape
4.2.1 Analysis by Doxorubicin Application
4.2.2 Analysis by Distribution Channel
5 Global Doxorubicin Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Doxorubicin Market Segmentation
6.1 Global Doxorubicin Market by Application
6.1.1 Market Overview
6.1.2 Ovarian Cancer
6.1.3 Multiple Myeloma
6.1.4 Kaposi Sarcoma
6.1.5 Leukaemia
6.1.6 Bone Sarcoma
6.1.7 Breast Cancer
6.1.8 Endometrial Cancer
6.1.9 Gastric Cancer
6.1.10 Liver Cancer
6.1.11 Kidney Cancer
6.1.12 Other Cancers
6.2 Global Doxorubicin Market by Distribution Channel
6.2.1 Market Overview
6.2.2 Hospital Pharmacy
6.2.3 Retail Pharmacy
6.2.4 Online Pharmacy
6.3 Global Doxorubicin Market by Region
6.3.1 Market Overview
6.3.2 North America
6.3.3 Europe
6.3.4 Asia Pacific
6.3.5 Latin America
6.3.6 Middle East and Africa
7 North America Doxorubicin Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Doxorubicin Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Doxorubicin Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Doxorubicin Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Doxorubicin Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Pfizer Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Sun Pharmaceutical Industries Limited
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Cipla, Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Cadila Pharmaceuticals Ltd.
17.4.1 Financial Analysis
17.4.2 Financial Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 SRS PHARMACEUTICALS PVT. LTD.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
18 Global Doxorubicin Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
Globally, doxorubicin market reached a value of USD 1,295.95 million in 2023.
The market is projected to expand at a CAGR of 6.4% from 2024 to 2032, growing to USD 2,264.98 million by 2032.
The market is being driven by the rising cases of cancer and the associated mortality rates, along with an increase in the number of breast cancer patients worldwide.
The industry is primarily being driven the supportive actions from the government for technological progress in clinical diagnostics and therapeutics.
The major regional markets for doxorubicin are North America, Latin America, the Asia Pacific, Europe, and the Middle East and Africa.
Doxorubicin finds its applications in the treatment of ovarian cancer, multiple myeloma, kaposi sarcoma, leukaemia, bone sarcoma, breast cancer, endometrial cancer, gastric cancer, liver cancer, and kidney cancer, among other types of cancers.
The major players in the industry are Pfizer Inc., Sun Pharmaceutical Industries Limited, Cipla, Inc., and Cadila Pharmaceuticals Ltd., among others.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER